Dr. Anthony Johnson

Anthony Johnson, DO, is a board-certified and fellowship-trained maternal-fetal medicine specialist with expertise in fetal surgery for complicated monochorionic multifetal pregnancies, twin-to-twin transfusion syndrome, selective fetal growth restriction, and fetoscopic endotracheal occlusion for congenital diaphragmatic hernia.
He is also a professor with the Department of Obstetrics, Gynecology and Reproductive Sciences at McGovern Medical School UTHealth Houston and the co-director of the UTHealth Houston Fetal Center.
Johnson is renowned in fetal surgery and maternal-fetal medicine. He is involved in a renal anhydramnios fetal therapy study about treatment for mothers and their babies affected by early pregnancy renal anhydramnios.
Before joining UTHealth Houston, Johnson was a professor at Baylor College of Medicine in Houston in the Department of Obstetrics and Gynecology, the Michael E. DeBakey Department of Surgery, and the Department of Molecular and Human Genetics.
Johnson …received his medical degree from West Virginia School of Osteopathic Medicine in Lewisburg. Subsequently, he completed his fellowship in Maternal-Fetal Medicine at Pennsylvania Hospital and a fellowship in medical genetics at Thomas Jefferson University Hospital, both in Philadelphia. He later served as the director of the Fetal Intervention Program in the Division of Maternal-Fetal Medicine at North Carolina Women’s Hospital in Chapel Hill, North Carolina, before moving to Houston in 2006.
Johnson is an examiner on the Maternal Fetal Medicine Subspecialty Committee of the American Osteopathic Board of Obstetrics and Gynecology and the Medical Advisory Board of the Fetal Health Foundation. He has served as director of the Society for Maternal-Fetal Medicine’s Special Interest Group in Maternal-Fetal Surgery and Special Interest Group in Genetics. He was also a reviewer of the National Institutes of Child Health and Human Development, which sponsored the Management of Myelomeningocele Study published in the New England Journal of Medicine in 2011. Additionally, Johnson was the 2023 recipient of the Lifetime Achievement Award from the North American Fetal Therapy Network (NAFTNET).